A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Clinical trial NCT04457869 · UNKNOWN

Trial details

NCT number: NCT04457869
Sponsor: Shandong New Time Pharmaceutical Co., LTD
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma

Start date: 2020-11-01
Primary completion: 2022-07-31
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.